Related references
Note: Only part of the references are listed.An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries
J. Connor Wells et al.
JAMA ONCOLOGY (2021)
The National Clinical Trials Network and the cooperative groups: The road not taken
Richard L. Schilsky
CANCER (2020)
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report
Monica M. Bertagnolli et al.
CANCER (2020)
Barriers to conducting cancer trials in Canada: an analysis of key informant interviews
C. Bentley et al.
CURRENT ONCOLOGY (2020)
Analysis of Global Pediatric Cancer Research and Publications
Eleni Syrimi et al.
JCO GLOBAL ONCOLOGY (2020)
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2019)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Discrepancies between Canadian cancer research funding and site-specific cancer burden: a spotlight on ten disease sites
A. C. Coronado et al.
CURRENT ONCOLOGY (2018)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Research output and the public health burden of cancer: is there any relationship?
F. M. Patafio et al.
CURRENT ONCOLOGY (2016)
The State State of Lung Cancer Research: A Global Analysis
Ajay Aggarwal et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Relevance of randomised controlled trials in oncology
Ian F. Tannock et al.
LANCET ONCOLOGY (2016)
Factors associated with publication of randomized phase III cancer trials in journals with a high impact factor
P. A. Tang et al.
CURRENT ONCOLOGY (2014)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding
Ashley J. R. Carter et al.
BMC PUBLIC HEALTH (2012)
Does Canadian research investment rebate to cancer burden?
Philip E. Branton
LANCET ONCOLOGY (2008)
Trends in the global funding and activity of cancer research
Seth Eckhouse et al.
MOLECULAR ONCOLOGY (2008)
Share Paper
